VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.03
+1.87
+3.73%
Closed 19:22 08/07 EDT
OPEN
50.08
PREV CLOSE
50.16
HIGH
52.16
LOW
49.75
VOLUME
457.07K
TURNOVER
--
52 WEEK HIGH
75.00
52 WEEK LOW
11.65
MARKET CAP
6.48B
P/E (TTM)
-8.3776
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VIR stock price target is 34.67 with a high estimate of 44.00 and a low estimate of 17.00.

EPS

VIR News

More
Got $10,000? Invest in These 3 Coronavirus Vaccine Stocks
MotleyFool.com · 07/29 13:13
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020
SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report finan
GlobeNewswire · 07/28 20:01
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
EU in talks with Moderna and others for COVID-19 vaccine supply
Reuters reports that the European Union (EU) is negotiating with Moderna (NASDAQ:MRNA), Sanofi (NASDAQ:SNY), Johnson & Johnson (NYSE:JNJ), BioNTech (NASDAQ
seekingalpha · 07/17 18:06
2 Top Cancer Treatment Stocks To Watch In July
MotleyFool.com · 07/14 15:14
Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors
GlobeNewswire · 07/10 21:02
Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire · 07/10 21:01
Moderna completes enrollment in mid-stage study of COVID-19 vaccine
In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicit
seekingalpha · 07/08 18:58

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About VIR

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.
More

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.